IRCT20200623047902N34RecruitingUnknown
Bioequivalence study of Fingolimod capsule 0.5 mg manufactured by Alborzzagros versus originator brand in healthy volunteers in the fasted condition
Alborz Zagros company0 sites24 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 55 years (—)
- Sex
- All
Inclusion Criteria
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to fingolimod
Investigators
Similar Trials
Recruiting
Unknown
Bioequivalence study of Fingolimod 0.5 mg capsuleIRCT20200105046010N92Abidi Company24
Not yet recruiting
Not Applicable
Study of absorption and elimination rate of Fingolimod 0.5-mg capsule in comparison with Fingolimod brand Capsule (Gilenya®).Bioequivalence study.IRCT20200407046981N26Zahravi pharmaceutical company24
Completed
Phase 1
Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of FingolimodHealthy VolunteersNCT03757338Asofarma S.A.I. y C.33
Not yet recruiting
Phase 1
A Bioequivalence Study of Two Formulations of 5 mg Montelukast Chewable Tablets in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai VolunteersTCTR20210720012Siriraj Institute of Clinical Research (SICRES)28
Recruiting
Unknown
Anagrelide capsule BioequivalenceIRCT20130313012810N30Modava Pharmaceutical Company24